INTRODUCTION
============

The gene most commonly associated with congenital *situs* defects, known as heterotaxy, in humans encodes the X-linked transcription factor ZIC3 (MIM 306955). Mouse models of *Zic3* dysfunction also result in heterotaxy, indicating conserved mammalian function of this protein. Deletion of the entire *ZIC3* locus in humans, or in the classical mouse mutant bent tail (*Bn*), results in heterotaxy, indicating that loss-of-function is the most likely pathogenic mechanism ([@b21-0060755]; [@b17-0060755]; [@b22-0060755]; [@b12-0060755]; [@b28-0060755]). To date, 12 *ZIC3* variant sequences have also been identified in heterotaxy-affected families: six missense, five nonsense and one frameshift \[caused by a two-nucleotide insert, which results in a premature termination codon (PTC) 182 nucleotides upstream from the wild-type transcription termination codon\] ([@b22-0060755]; [@b34-0060755]; [@b46-0060755]; [@b13-0060755]). The functional significance of the 12 variant sequences has been investigated *in vitro* using mutant proteins expressed from ZIC3 full-length cDNAs containing each relevant mutation ([@b46-0060755]; [@b13-0060755]). The *in vivo* consequence of the mutations that produce a PTC-containing transcript is, however, hard to predict from these analyses. *In vivo* these mutant transcripts might be subjected to nonsense-mediated decay (NMD), whereas the cDNA variants used to model these mutations would typically evade NMD, which, in mammalian cells, appears dependent upon mRNA splicing ([@b38-0060755]).

NMD is a method of gene regulation and surveillance that recognizes and rapidly decays PTC-containing transcripts ([@b18-0060755]; [@b33-0060755]). One purpose of NMD is to limit the formation of C-terminally truncated polypeptides that might possess deleterious gain-of-function or dominant-negative activity. The mechanism by which a normal stop codon is distinguished from a premature one appears dependent upon the position of the PTC; a transcript will be committed to decay if a PTC is situated more than about 50--55 nucleotides upstream of an exon-exon junction ([@b37-0060755]). Because the rules regarding PTC recognition are not completely understood, the NMD sensitivity of PTC-containing transcripts needs to be assessed on a case-by-case basis ([@b25-0060755]). Moreover, not only do transcripts differ in their intrinsic sensitivity to NMD, the efficiency of NMD with respect to a given transcript can vary between tissues. To determine the functional significance of a nonsense mutation, RNA and/or protein levels must therefore be documented in the tissue and stage of development relevant to the particular disorder ([@b6-0060755]). For heterotaxy cases, this requires assessing mRNA or protein levels at gastrulation (the time of left-right axis formation); a task not possible for human cases of heterotaxy. If the identified *ZIC3* PTC-containing transcripts evade NMD, they might code for a ZIC3 molecule with a hypermorphic, hypomorphic or dominant-negative effect.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Heterotaxy, or *situs ambiguous*, refers to a group of rare congenital defects that are characterized by abnormal organ distribution. In heterotaxy, the normal, asymmetric position of organs (known as *situs solitus*) is disrupted, and this typically causes severe congenital heart disease that is sometimes accompanied by malformation of other organs. The most commonly mutated gene in heterotaxy is *ZIC3*, which encodes an X-linked transcription factor that plays a role in embryonic development. Half of the heterotaxy-associated *ZIC3* mutations identified to date introduce a premature termination codon (PTC) and the aberrant transcripts are expected to undergo nonsense-mediated decay (NMD). NMD of PTC-containing mRNAs varies in a transcript-, tissue- and stage-dependent manner and incomplete NMD can produce truncated proteins of unknown function. The presence of truncated proteins with varied functional abilities could underlie the remarkable phenotypic diversity observed in cases of heterotaxy.

**Results**

This study utilizes a novel model of murine *Zic3* dysfunction, called katun, which harbours a point mutation that introduces a premature stop codon into the *Zic3* transcript. Based on the presence of this PTC, the transcript was predicted to undergo NMD. However, the authors show that at the embryonic stage of left-right axis formation (during which organ asymmetry is established), the transcript evades NMD and a stable truncated protein is generated. They show that the truncated protein lacks endogenous function yet does not interfere with other coexpressed Zic proteins. The authors' analysis of all known PTC-containing *ZIC3* mutations provided the same result: all of the truncated proteins behaved as partial or complete loss-of-function mutants that did not interfere with wild-type ZIC3 function.

**Implications and future directions**

These results suggest that ZIC3-associated heterotaxy arises due to partial or complete loss of ZIC3 function, and not as a consequence of dominant-negative effects. The work also demonstrates the importance of investigating whether PTC-incorporating mutations lead to NMD *in vivo* (at the relevant stage and in the appropriate tissue type), rather than assuming that PTC-containing transcripts will be subject to NMD and will generate a null allele. The katun mouse strain will serve as a useful model for further investigations into the molecular pathways underlying ZIC3-associated heterotaxy, and for studies of Zic protein interactions and transcriptional surveillance mechanisms.

There is some evidence from the study of *Xenopus zic3* and murine *Zic2* that it is possible to produce a dominant-negative Zic molecule ([@b27-0060755]; [@b15-0060755]; [@b11-0060755]). The X-linked location of *Zic3* in humans and mice dictate, however, that the gene is not generally bi-allelically expressed and it is therefore unlikely that the putative dominant-negative activity could affect Zic3 function *in vivo*. Males are hemizygous for the maternal copy of *ZIC3*, and females (after random X-inactivation occurs in the embryo proper at implantation) are chimeric for cells that express either the mutant or the wild-type *Zic3* allele. *Zic3*, however, shares significant sequence homology with four other members of the mammalian Zic gene family (*Zic1*, *Zic2*, *Zic4* and *Zic5*) ([@b3-0060755]; [@b4-0060755]; [@b20-0060755]; [@b1-0060755]). The five genes show extensive homology throughout the DNA binding zinc fingers and *Zic1*, *Zic2* and *Zic3* also contain a conserved region within the N-terminal portion of the protein called the ZOC motif ([@b5-0060755]). The coexpression of family members could, therefore, enable a dominant-negative Zic3 molecule to interfere with the function of other Zic proteins. At the time of axis formation, *Zic3* is extensively coexpressed with *Zic2* and *Zic5* ([@b20-0060755]; [@b16-0060755]). Some cases of heterotaxy could therefore result from a composite phenotype due to deleterious effects on not only ZIC3 function but also on one or more additional family members. This scenario could partially explain the extreme phenotypic variability associated with *ZIC3* cases of heterotaxy ([@b46-0060755]).

Here, we show that the katun (*Ka*) mouse mutant ([@b10-0060755]) harbours a mutation in the *Zic3* gene that introduces a PTC. At the time of left-right axis formation, the mutant transcript is not subjected to NMD, predicting the production of a mutant protein during embryogenesis. When the analogous mutant cDNA is expressed in cultured mammalian cell lines, a stable protein that is truncated just two amino acids upstream of the zinc finger domain is produced. The truncated protein lacks the zinc finger domain and should fail to undergo nuclear import ([@b7-0060755]); however, it accumulates within the nucleus as a result of passive diffusion. Despite its presence in the nucleus, the katun protein is unable to elicit transcription of a ZIC3 target promoter and does not compete with the wild-type trans-activation ability of the ZIC3, ZIC2 or ZIC5 proteins, indicating that the N-terminal portion of ZIC3 does not possess dominant-negative activity. Additionally, the katun protein fails to inhibit Wnt-mediated transcription, unlike wild-type ZIC3 protein. The phenotype of katun mutant embryos replicates that of a targeted null allele of *Zic3* and confirms that the *Ka* mutant phenotype results from a loss of *Zic3* activity alone.

The relative ability of a transcript to undergo NMD is influenced by sequences within the transcript that promote RNA splicing, such as splice donor and acceptor sites ([@b23-0060755]). The murine *Zic3* and human *ZIC3* transcripts contain identical splice sites so the finding that the murine *Zic3* transcript is relatively insensitive to NMD during axis formation and early organogenesis suggests that the human transcript also evades NMD at these stages of embryogenesis. This prompted the examination of other truncated ZIC3 proteins predicted in human heterotaxy cases and none were found to possess dominant-negative activity. The data suggest that ZIC3-associated heterotaxy caused by nonsense or frameshift mutations affects ZIC3 function alone. The katun mutant is useful not only for investigations into the molecular mechanisms underlying ZIC3-associated heterotaxy but also for studies of Zic protein interaction and transcriptional surveillance mechanisms.

RESULTS
=======

The *Zic3* gene is mutated in the katun mouse strain
----------------------------------------------------

The katun allele arose as a spontaneous, X-linked mutation during an *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis experiment ([@b10-0060755]), indicating that it might be a new allele of *Zic3*, the gene deleted in the classical, X-linked mouse mutant bent tail (*Bn*) ([@b12-0060755]; [@b28-0060755]) and mutated in targeted mouse strains ([@b40-0060755]; [@b52-0060755]). The coding region of *Zic3* was amplified from the genomic DNA of a heterozygous female, a hemizygous male, a C3H mouse and a BALB/c mouse and sequenced. This revealed a single base change of guanine (G) to thymine (T) at nucleotide position 1283 (1283G \>T) of accession number NM_009575 in the affected animals ([Fig. 1A--C](#f1-0060755){ref-type="fig"}). The colony has subsequently been maintained via genotyping of this variant, and non-segregation between the phenotype and mutation found in more than 1000 meioses. A further five strains of mice (Mus Castaneus, Mus Spretus, C57BL/6J, 129Sv and 101/H) were analysed and none were found to contain the variant allele, eliminating the possibility that the variant is a naturally occurring polymorphism. The identified base change introduces a PTC at amino acid 249 (E249X) and, if translated, would cause termination of the protein sequence just two amino acids upstream of the zinc finger domain ([Fig. 1D](#f1-0060755){ref-type="fig"}).

![**The katun mouse strain carries a mutation in *Zic3***. (A--C) Sequence traces from exon 1 of the murine *Zic3* gene, with arrows indicating the altered base. (A) The parental C3H/HeH and BALB/c OlaHsd alleles have a G at position 1283 of accession number NM_009575. (B) Female carriers of the mutation have a G/T heteroduplex at this position. (C) Male hemizygotes have a G to T transversion at this position. (D) Representation of the Zic3 protein showing the position of the katun (E249X) mutation relative to other protein features, including the C2H2 zinc fingers (dark blue), amino acid repeat regions (blue; A, alanine repeat; H, histidine repeat), the Zic-Opa conserved (ZOC) motif (bright green) and the zinc finger N-flanking conserved (ZF-NC) region (light green).](DMM011668F1){#f1-0060755}

The katun transcript evades nonsense-mediated decay
---------------------------------------------------

The katun transcript conforms to the rule for NMD ([@b37-0060755]) and is predicted to be absent from hemizygous null embryos. To determine whether the katun transcript is subjected to NMD we performed whole mount *in situ* hybridization (WMISH) to *Zic3* in wild-type and *Ka/Y* embryos (7.0, 8.5, and 9.5 days post-conception; dpc). As shown in [Fig. 2A--E](#f2-0060755){ref-type="fig"}, *Zic3* transcript levels were indistinguishable from wild-type levels in the hemizygous null embryos at all stages examined, suggesting that NMD of the *Ka* transcript is deficient. To confirm this, allele-specific RT-PCR was performed at each of the embryonic stages examined by WMISH from embryos of all three genotypes (*+/+*, *Ka/X* and *Ka/Y*). The absence of genomic DNA in each sample was confirmed by amplification of an intron spanning fragment from the *Zic3* gene. The 162-bp cDNA-specific product was only amplified from cDNA samples synthesized in the presence of reverse transcriptase, whereas the 1006-bp genomic DNA-specific product was absent in all samples ([Fig. 2F](#f2-0060755){ref-type="fig"} and data not shown). Allele-specific RT-PCR products were then produced (using exon 1 primers) from each RNA sample and analysed by high resolution melt analysis. In each case, the melt profile of the products obtained from cDNA samples was compared with positive control profiles obtained from genomic DNA of animals of known genotype ([Fig. 2G](#f2-0060755){ref-type="fig"}). At 7.5, 8.5 and 9.5 dpc, embryos containing only the mutant *Zic3* allele (*Zic3^Ka/Y^*) exclusively express the *Ka* transcript, embryos containing only the normal *Zic3* allele (*Zic3^+/+^*) exclusively express the wild-type transcript whereas embryos with one mutant and one wild-type allele (*Zic3^Ka/X^*) express a mixture of the two transcripts ([Fig. 2G--J](#f2-0060755){ref-type="fig"}). The hybridization signal seen in *Zic3^Ka/Y^* mutant embryos is therefore due to the accumulation of the *Ka* transcript. Together, these data indicate that the *Ka* transcript is not rapidly subjected to NMD during axis formation (the stage at which the *Zic3*-associated heterotaxy phenotype emerges).

![**The katun PTC-containing transcript accumulates in gastrulation and organogenesis stage mutant embryos.** (A--E) Lateral views of embryos after WMISH to *Zic3* RNA; embryos are shown with anterior to the left (A,B,D,E) or top (C). (A,B) 7.0 dpc embryos of the genotype indicated on the panel. (C) 8.5 dpc embryos of the genotype indicated on the panel. (D,E) 9.5 dpc embryos of the genotype indicated on the panel. (F) PCR amplification of an intron-spanning product from the *Zic3* gene (generated with primers Ark364 and Ark311; expected product size for genomic DNA is 1006 bp and for cDNA is 162 bp) following cDNA synthesis from each of the RNAs used for allele-specific PCR. --RT, without reverse transcriptase; +RT, with reverse transcriptase; g, genomic DNA; n, no template control; m, size marker. (G--J) Melting peak analysis following high resolution melting of *Zic3* allele-specific PCR products (generated with primers Ark1085 and Ark1086). The *Zic3^+/+^* DNA melt profiles are shown in gray, the *Zic3^Ka/Y^* DNA melt profiles in blue and the *Zic3^Ka/X^* profiles in red. (G) *Zic3* amplicons after PCR of genomic DNA isolated from three *Zic3^+/+^* mice, three *Zic3^Ka/X^* mice or three *Zic3^Ka/Y^* mice. (H) *Zic3* amplicons after PCR of cDNAs synthesized from 7.5 dpc RNA. (I) *Zic3* amplicons after PCR of cDNAs synthesized from 8.5 dpc RNA. (J) *Zic3* amplicons after PCR of cDNAs synthesized from 9.5 dpc RNA. (K) Diagram of the murine *Zic3* genomic locus showing the location of the mutation and the primers used for allele-specific and intron-spanning RT-PCR.](DMM011668F2){#f2-0060755}

The mutant protein is stable and accumulates in the nucleus via passive diffusion
---------------------------------------------------------------------------------

The finding of incomplete NMD raises the possibility that the message could be translated into a short-lived, truncated protein with some function. Detection of Zic3 protein in wild-type and katun mutant embryos using SDS-PAGE and western blotting was not successful due to failure of the antibodies to specifically detect endogenous Zic3 (data not shown). Therefore, to determine whether this mutant Zic3 transcript can be translated into a stable protein, either a N-terminal V5-epitope tagged version of ZIC3 (V5-ZIC3-wt) or ZIC3-katun variant (V5-ZIC3-katun) were expressed in cultured mammalian cell lines. Following transfection of COS-7, HEK293T or NIH 3T3 cells a wild-type protein of ∼60 kDa and a katun protein of ∼35 kDa were detected with western blotting using either an anti-Zic3 antibody or an anti-V5 antibody. Both proteins were detected in lysates made 24, 42 and 72 hours post-transfection, indicating that the katun protein is stable ([Fig. 3A](#f3-0060755){ref-type="fig"} and data not shown). The predicted sizes of the wild-type and katun ZIC3 proteins are 52 kDa and 27 kDa, respectively, with the difference corresponding to the size of the V5 tag and spacer fragment within the pcDNA3.1/nV5-DEST vector.

![**Truncated katun protein diffuses into the nucleus.** (A) HEK293T cells expressing either V5-ZIC3-wt or V5-ZIC3-katun were lysed to generate nuclear (N) and cytoplasmic (C) fractions. Lysates were then subjected to SDS-PAGE and western blotting with anti-V5 antibodies. (B) HEK293T cells expressing V5- or EGFP-tagged ZIC3 constructs were co-immunostained with anti-lamin B antibody (to detect nuclear envelope, in red) and either anti-V5 or anti-GFP antibodies (in green). Overlaid images are shown. (C) HEK293T cells expressing either EGFP-ZIC3-wt or EGFP-ZIC3-katun were lysed and fractionated into nuclear (N) and cytoplasmic (C) fractions. Lysates were then subjected to SDS-PAGE and western blotting with anti-GFP antibodies. (D) Localization of V5-ZIC3-wt or V5-ZIC3-katun in nuclear (gray) and cytoplasmic (black) compartments of HEK293T cells was quantified using ImageJ. \**P*\<0.01 using ANOVA.](DMM011668F3){#f3-0060755}

The Zic3 protein does not contain a canonical nuclear localization signal but is transported into the nucleus via the importin pathway through cryptic nuclear localization signals within the zinc finger domain ([@b7-0060755]; [@b24-0060755]). The absence of the zinc finger domain in the katun protein is therefore expected to prevent accumulation of V5-ZIC3-katun within the nucleus. As shown in [Fig. 3A](#f3-0060755){ref-type="fig"}, subcellular fractionation of transfected cell lysates revealed that a significant proportion of the katun protein was found in the nucleus. To confirm this result and quantify the extent of katun nuclear accumulation, the subcellular localization of V5-ZIC3-katun was compared with that of V5-ZIC3-wt by immunofluorescent staining following transfection into HEK293T cells ([Fig. 3B,D](#f3-0060755){ref-type="fig"}). Consistent with previous studies on the subcellular location of Zic proteins ([@b46-0060755]), 88.5% of the wild-type V5-ZIC3-wt protein was found within the nucleus. Strikingly, 61.4% of the mutant V5-ZIC3-katun protein accumulated within the nucleus. This raised the possibility that the N-terminal portion of Zic3 contains sequences sufficient for directed nuclear transport. It is, however, also possible that the small size of the katun protein enables it to diffuse into the nucleus because proteins smaller than ∼40 kDa can diffuse into the nucleus ([@b49-0060755]). To distinguish between these possibilities, the size of the katun protein was artificially increased by fusion with enhanced green fluorescent protein (EGFP). The subcellular localization of EGFP-ZIC3-katun was compared with that of EGFP-ZIC3-wt following transfection into HEK293T cells using western blot and immunofluorescent staining ([Fig. 3B--D](#f3-0060755){ref-type="fig"}). Western blot analysis detected EGFP-ZIC3-wt in the nuclear fraction at ∼85 kDa (predicted size, 79 kDa) and EGFP-katun predominately in the cytoplasmic fraction at ∼55 kDa (predicted size, 54 kDa). Immunofluorescent localization analysis found that 88.9% of the EGFP-ZIC3-wt protein was within the nucleus, whereas only 10.3% of the mutant EGFP-ZIC3-katun protein accumulated within the nucleus. The difference between the localization of the V5-ZIC3-katun protein and the EGFP-ZIC3-katun protein suggests that the katun protein accumulates in the nucleus by passive diffusion.

The mutant protein is transcriptionally inactive and does not compete with wild-type ZIC3
-----------------------------------------------------------------------------------------

Given that the katun protein is stable and localizes to the nucleus, it is possible that the protein exerts some effect. The zinc finger domain is crucial for the trans-activation ability of Zic proteins because deletion of the domain or point mutations within the zinc fingers that disrupt DNA binding leads to proteins that are unable to stimulate transcription ([@b11-0060755]). The ability of V5-ZIC3-katun to stimulate transcription was evaluated using a well-established cell-based Apoe promoter luciferase reporter assay ([@b42-0060755]; [@b11-0060755]). Co-transfection of the Apoe reporter construct with either the V5-ZIC3-wt construct or the V5-ZIC3-katun construct into HEK293T cells followed by quantification of luciferase activity demonstrated that the truncated protein was unable to elicit transcription ([Fig. 4A](#f4-0060755){ref-type="fig"}). The comparable expression of each ZIC3 construct was confirmed by SDS-PAGE and western blot ([Fig. 4A](#f4-0060755){ref-type="fig"}, Blot). When V5-ZIC3-katun was placed in competition with wild-type ZIC proteins (V5-ZIC3-wt, V5-ZIC2-wt or V5-ZIC5-wt) the trans-activation abilities of the wild-type proteins were not significantly altered ([Fig. 4B](#f4-0060755){ref-type="fig"}).

![**The katun protein is functionally inert.** (A) Trans-activation assay in HEK293T cells co-transfected with the *Apoe* reporter construct and the expression plasmids shown. The anti-V5 western blot shows the level of overexpressed proteins and the anti-TBP western blot acts as a nuclear fraction loading control. (B) Competition assay in HEK293T cells co-transfected with the *Apoe* reporter construct and the expression plasmids shown. The anti-V5 western blot shows the level of overexpressed proteins and the anti-TBP western blot acts as a loading control. (C) Wnt inhibition assay in HEK293T cells co-transfected with either TOPflash or FOPflash reporter construct and the expression plasmids shown. The anti-V5 and anti-β-catenin western blots show the level of overexpressed proteins in the nuclear and cytoplasmic fractions, respectively. The anti-TBP and anti-β-tubulin western blots act as nuclear and cytoplasmic loading controls, respectively. Anti-β-catenin detects both endogenous β-catenin and the smaller exogenously expressed β-catenin-ΔN89 (marked by arrows). Error bars denote s.d. between internal replicates; \**P*\<0.01 using ANOVA.](DMM011668F4){#f4-0060755}

The mutant protein does not inhibit β-catenin-mediated transcription
--------------------------------------------------------------------

The human ZIC2 and *Xenopus* zic1-5 proteins have recently been shown to act as cofactors that inhibit Wnt-dependent-β-catenin-mediated transcription ([@b39-0060755]; [@b19-0060755]). Upon Wnt stimulation, β-catenin enters the nucleus and interacts with the TCF transcription factors to stimulate transcription of target genes ([@b8-0060755]). A luciferase reporter construct containing consensus TCF binding sites (TOPflash) or mutated TCF sites (FOPflash) is routinely used to assess Wnt-dependent transcription ([@b29-0060755]). Co-transfection of the TOPflash construct with one encoding a stabilized form of β-catenin (β-catenin-ΔN89) into HEK293T cells drove high levels of luciferase activity ([Fig. 4C](#f4-0060755){ref-type="fig"}) but this level was not attained in the presence of V5-ZIC3-wt. This indicates that human ZIC3, like ZIC2, is able to inhibit β-catenin-mediated transcription of Wnt target genes in cultured HEK293T cells. In addition, when ZIC3 is expressed, lower levels of β-catenin-ΔN89 are detected, which is consistent with the enhanced β-catenin degradation previously seen with the expression of *Xenopus* zic3 ([@b19-0060755]). In contrast to wild-type ZIC3 protein, co-transfection with V5-ZIC3-katun does not decrease luciferase activity, indicating that the katun protein is unable to inhibit Wnt-dependent β-catenin-mediated transcription.

*Ka* phenocopies a targeted null allele of *Zic3*
-------------------------------------------------

The most definitive test of allele type involves placing the new allele in *trans* to a known null allele, but this test cannot be performed for X-linked genes. To determine whether the *Ka* allele of *Zic3* behaves as a null mutation *in vivo* we therefore recovered embryos at gastrulation stages and examined the associated phenotype. The allele of *Zic3* that is best characterized at these stages is the targeted null allele of *Zic3* (*Zic3^tm1Bca^*) ([@b40-0060755]). Embryos from this strain that are hemizygous or homozygous null have a variable phenotype, with mutant embryos being assigned to three classes. Type I and Type II embryos display aberrant morphology at early and mid-gastrula stages, whereas the Type III embryos are not morphologically abnormal until the end of gastrulation. The Type I and Type II embryos are characterized by defects in the endoderm and mesoderm formed during gastrulation ([@b48-0060755]). When embryos hemizygous for the *Ka* allele (*Zic3^Ka/Y^*) were recovered at gastrulation a highly variable phenotype was apparent. A proportion of the recovered embryos displayed defects of the distal egg cylinder or of the extra-embryonic/embryonic junction that are characteristic of the Type I and Type II embryos, as described previously ([@b48-0060755]). 100% of these embryos were of the *Zic3^Ka/Y^* genotype.

To confirm that the phenotype observed in the *Zic3^Ka/Y^* embryos is analogous to that described for embryos from the targeted null allele, WMISH to markers of endoderm and mesoderm formation was performed (a minimum of four embryos were examined per genotype class and probe). Embryos that had morphological defects characteristic of type I mutants were analysed by hybridization to probes to detect *Cer1* and *Lim1* expression ([Fig. 5A,B](#f5-0060755){ref-type="fig"}). At this stage of development, both of these genes are expressed in the anterior visceral endoderm (AVE) at the embryonic anterior (arrows in [Fig. 5A,B](#f5-0060755){ref-type="fig"}). This expression was either lacking or markedly reduced in all mutant embryos examined. *Cer1* is also expressed in the emerging definitive endoderm and *Lim1* is expressed in the wings of developing embryonic mesoderm and this expression was also disrupted in Type I *Zic3^Ka/Y^* embryos ([Fig. 5A,B](#f5-0060755){ref-type="fig"}). Embryos that had morphological defects characteristic of Type II embryos were analysed by hybridization to probes that mark the primitive streak and emerging wings of embryonic mesoderm (*Fgf8* and *Foxa2*). Consistent with previous analysis ([@b48-0060755]), Type II embryos exhibited mesoderm abnormalities that included a protrusion of the primitive streak into the amniotic cavity ([Fig. 5C](#f5-0060755){ref-type="fig"}) and ectopic expression of mesoderm markers (arrows in [Fig. 5D,E](#f5-0060755){ref-type="fig"}). Additional embryos (*n*=65 *Zic3^+/+^* and *n*=27 *Zic3^Ka/Y^*) were recovered at 9.5 dpc and the heart examined for looping defects indicative of heterotaxy. Consistent with previous analysis of a Zic3 null allele ([@b47-0060755]), 52% of null embryos exhibited normal hearts (dextral looping, [Fig. 5F](#f5-0060755){ref-type="fig"}), 19% exhibited a leftward curve of the heart tube (sinistral looping, [Fig. 5G](#f5-0060755){ref-type="fig"}) and the remaining 30% had a heart tube that looped forward (ventral looping) or did not loop at all.

![**The katun mutant embryos have altered primitive streak, mesoderm and endoderm formation.** (A--G) All embryos are shown in lateral view, anterior to the left, following *in situ* hybridization to the RNA named on each panel. (A) Wild-type and type I mutant embryo, 7.0 dpc. (B) Wild-type and type I mutant embryo, 7.0 dpc. Arrows in A and B mark the anterior visceral endoderm (AVE). (C) Wild-type and type II mutant embryo, 7.5 dpc. (D) Wild-type and type II mutant embryo, 7.0 dpc. (E) Wild-type and type II mutant embryo, 7.0 dpc. Arrows in D and E point to regions of ectopic expression of mesoderm markers. (F,G) Developing hearts of 9.5-dpc embryos of the genotype indicated (photographed following *in situ* hybridization to mRNAs not expressed in the heart; the signal seen is nonspecific). R, right ventricle; L, left ventricle.](DMM011668F5){#f5-0060755}

PTC-containing *ZIC3* mutant transcripts produce proteins that do not compete with wild-type ZIC3
-------------------------------------------------------------------------------------------------

The magnitude of NMD is dependent upon the strength of the splice donor and acceptor sites within an intron, with stronger sites (i.e. those that more closely match the consensus sequence) subject to increased NMD ([@b23-0060755]). To assess whether inefficient NMD of the human *ZIC3* can be predicted, the mouse *Zic3* and human *ZIC3* splice sites were compared. As shown in [Table 1](#t1-0060755){ref-type="table"}, the sites are identical (intron 1/2 and 2/3) or nearly so (intron 2/4). Intron 2/3 has the weakest splice signals, as indicated by a lower consensus value score. The absolute conservation of *Zic3* and *ZIC3* splice sites prompted the examination of the predicted proteins from each of the *ZIC3*-associated heterotaxy mutations that generate a PTC. Six different *ZIC3*-associated heterotaxy mutations with a PTC have been previously documented and the protein stability, subcellular localization and transcriptional ability of each of these has been assessed using cell-based assays. Two of these mutations generate unstable proteins (S43X and Q249X) whereas the remaining mutations generate stable proteins that can either be found exclusively in the cytoplasm (C268X and Q292X) or in both cytoplasmic and nuclear compartments (1507insTT and K408X) ([@b46-0060755]). To test whether any of these proteins possess dominant-negative properties, the analogous mutant proteins were expressed in HEK293T in competition with wild-type ZIC3. Expression of each ZIC3 construct was verified by SDS-PAGE and western blot of lysates containing both nuclear and cytoplasmic fractions. Note that the Q249X mutation was excluded from this analysis because it is probably well-modelled by experiments with the V5-ZIC3-katun construct. Our results confirm the finding of Ware and colleagues that the K408X protein retains some trans-activation ability ([@b46-0060755]). Importantly, co-transfection of each ZIC3 mutant construct (V5-ZIC3-C268X, V5-ZIC3-Q292X, V5-ZIC3-1507insTT and V5-ZIC3-K408X) with wild-type ZIC3 (V5-ZIC3-wt) demonstrated that none of the mutant proteins significantly alter the ability of wild-type ZIC3 to activate transcription ([Fig. 6](#f6-0060755){ref-type="fig"}).

###### 

*Zic3*/*ZIC3* splice site homology and scores

![](DMM011668T1)

![**ZIC3-heterotaxy-associated mutant proteins do not compete with wild-type ZIC.** Competition assay using HEK293T cells co-transfected with the *Apoe* reporter construct and the expression plasmids shown. The anti-V5 western blot shows the level of overexpressed proteins and the anti-TBP western blot acts as a loading control. Arrow marks the position of V5-ZIC3-wt in the blot. Error bars denote s.d. between internal replicates. a, *P*\<0.01 using ANOVA, compared with V5-ZIC3-wt. b, *P*\<0.001 using ANOVA, compared with V5-ZIC3-wt and other ZIC3 mutants.](DMM011668F6){#f6-0060755}

DISCUSSION
==========

The katun mouse strain carries a null allele of *Zic3*
------------------------------------------------------

The katun mouse strain arose spontaneously during an ENU-mutagenesis experiment ([@b10-0060755]). We show here that the identified phenotype (a bent tail) is caused by mutation of the X-linked *Zic3* gene. Several lines of evidence indicate that the identified mutation is responsible for the phenotype: (i) the identified base pair change is not a commonly occurring polymorphism; (ii) the variant segregates with the phenotype, being linked through over 1000 meioses to date during maintenance of the colony; (iii) the identified nonsense mutation generates an inactive protein; and (iv) the phenotype precisely recapitulates that documented for a pre-existing null allele of *Zic3*.

The katun mutation introduces a nonsense codon into the *Zic3* transcript that conforms to the rule for PTC recognition in mammalian cells. This provides the first opportunity to investigate the fate of such *Zic3* transcripts during mammalian axis formation. WMISH to *Zic3* in *Ka/Y* embryos at gastrulation and early organogenesis stages showed no decrement in *Zic3* mRNA accumulation. Allele-specific RT-PCR confirmed that the only transcript expressed in *Ka/Y* embryos carries the nonsense mutation and that both wild-type and mutant transcripts are present in *Ka/X* embryos. These data indicate that the *Zic3* transcript is a poor substrate for NMD at the time of left-right axis formation and raise the possibility that the *Ka* mutation does not represent a null allele. Investigations into the molecular properties of the katun mutant protein confirmed, however, that it lacks activities associated with wild-type ZIC3. The katun protein is truncated just two amino acid residues upstream of the zinc finger domain that is required for nuclear localization ([@b7-0060755]; [@b24-0060755]), trans-activation of target gene expression ([@b31-0060755]; [@b35-0060755]; [@b46-0060755]) and inhibition of β-catenin-mediated transcription ([@b19-0060755]). Although katun can accumulate in the nucleus to appreciable levels (due to passive diffusion rather than active transport), it is transcriptionally inert and does not inhibit β-catenin-mediated transcription.

These data establish that the katun protein is null for the known Zic3 molecular activities, but *Xenopus* experiments have implied that a similar zic3 protein interferes with the function of wild-type zic3 during axis formation ([@b27-0060755]). This possibility has not previously been biochemically tested. When the katun mutant protein is placed in competition with either wild-type ZIC3 or the other ZIC molecules coexpressed at the time of axis formation (ZIC2 and ZIC5), it does not interfere with their ability to activate transcription of a target promoter in HEK293T cells. More rigorous evidence that the katun protein does not dominantly interfere with the activity of other Zic proteins comes from the *in vivo* studies presented here. Experiments that decrease Zic2 activity in a Zic3 null background indicate that these two molecules exhibit partial redundancy during murine axis formation ([@b26-0060755]). If the katun protein interferes with Zic2 function *in vivo* then the *Ka* strain should exhibit a more severe phenotype than other known *Zic3* null alleles. Analysis of the phenotype of the *Ka/Y* embryos shows that it mimics a null allele of *Zic3* in several precise details and indicates that that the *Ka* allele alters the function of Zic3 alone. Together, the phenotype and protein studies demonstrate that *Ka* encodes a null allele of *Zic3* and that the N-terminal portion of mammalian Zic3 does not encode a dominant-negative molecule.

The possibility of incomplete NMD influences the interpretation of *ZIC3* PTC-inducing mutations
------------------------------------------------------------------------------------------------

The finding that the murine *Zic3* transcript is a poor substrate for NMD at axis formation suggests that this is also the case for the human *ZIC3* transcript. Direct assessment of the fate of human *ZIC3* PTC-containing transcripts during axis formation is not possible and predictions regarding the likely NMD behaviour based on the murine transcript provide one alternative. The features that render a transcript a poor target for NMD are not fully characterized. There is, however, evidence that the position of the PTC within the transcript and RNA splicing influences NMD amplitude ([@b37-0060755]; [@b23-0060755]). The genomic arrangement of the murine (*Zic3*) and human (*ZIC3*) genes is nearly identical and the splice donor and acceptor sites are completely conserved. It is likely that the human *ZIC3* transcript is similarly able to avoid mRNA surveillance mechanisms, which needs to be considered when interpreting the probable effect of *ZIC3* PTC-inducing mutations. If PTC-containing transcripts are translated, the two most likely effects are: (i) proteins that truncate downstream of crucial domains might be hypomorphic; and (ii) proteins that do not produce crucial domains might encode dominant-negative molecules.

Six mutations that introduce a PTC into the human ZIC3 transcript have been associated with congenital defects. Four of these adhere to the position rule for NMD (i.e. the PTC is sited more than about 50--55 nucleotides upstream of an exon-exon junction ([@b37-0060755]). The most 5′-ward of the mutations (C633A) would encode a severely truncated molecule (S43X) if not degraded. Previous examination of this putative protein has shown that it is not stably produced in cell lines ([@b46-0060755]) and is therefore likely to generate a null allele regardless of NMD amplitude. The C1250T mutation would encode the Q249X protein. An expression construct incorporating this mutation into the *ZIC3* cDNA has previously been reported to produce no protein ([@b46-0060755]). This PTC lies very close to that generated here in order to mimic the katun protein (E250X), but the katun mutation results in a stable protein. Whatever the reason for the discrepancy between these results, the studies of the katun protein suggest that even if the Q249X protein is generated *in vivo* it would encode a protein with neither transcriptional Wnt inhibition nor dominant-negative activity. The remaining two mutations (C1338A and C1408T) that conform to the NMD PTC position rule would generate proteins that contain part of the zinc finger domain (C268X and Q292X, respectively). Previous studies indicate that these proteins are transcriptionally inactive and here we confirm and extend this analysis to show that these proteins also fail to dominantly interfere with ZIC trans-activation ability. It seems likely that each of these four mutations would generate a null allele of *ZIC3* regardless of NMD amplitude and not result in a composite ZIC phenotype. The remaining two mutations (1507insTT and A1741T) introduce a PTC close to the last intron and, regardless of *ZIC3* transcript sensitivity to NMD, are likely to be translated into a stable protein. Here, we confirm that the frameshift protein is transcriptionally inert whereas the K408X protein (corresponding to the A1741T mutation) retains some trans-activation ability. Neither protein is able to interfere with the trans-activation ability of wild-type ZIC. The frameshift mutation therefore appears to generate a null allele whereas the K408X mutation is predicted to be hypomorphic. This conclusion is consistent with the finding of incomplete penetrance for the A1741T mutation ([@b34-0060755]).

In summary, the work presented here confirms the notion that loss of function (partial or complete) of *ZIC3* alone is the probable mode of pathology in *ZIC3*-associated heterotaxy cases that involve PTC-containing transcripts. It implies, however, that *ZIC3* PTC-inducing mutations cannot, *a priori*, be considered to encode a null allele. It is possible that the *ZIC3* transcript, like *Zic3*, is a poor substrate for NMD at the axis formation stage of embryogenesis. Instead, each putative protein needs to be evaluated for its trans-activation ability, co-repressor ability and potential dominant-negative effects. Analysis of the phenotype associated with a murine PTC-containing transcript suggests that the N-terminal portion of the Zic3 protein that lies upstream of the zinc finger does not possess dominant-negative activity and does not interfere with the function of other coexpressed Zic proteins.

MATERIALS AND METHODS
=====================

Mouse strains and husbandry
---------------------------

Mice were maintained according to Australian Standards for Animal Care under protocol A2011/63 approved by The Australian National University Animal Ethics and Experimentation Committee for this study. The katun (*Ka*) allele (MGI:3043027) of *Zic3* (*Zic3^Ka^*) was maintained by continuous backcross to C57BL/6J inbred mice; animals from backcross 10 and beyond were used for analysis. Mice were maintained in a 12-hour light-dark cycle, the midpoint of the dark cycle being 1 am. For the production of staged embryos, 1 pm on the day of appearance of the vaginal plug was designated 0.5 dpc. Genomic DNA was prepared for genotyping as previously described ([@b2-0060755]) and amplified for high resolution melt analysis using IMMOLASE™ DNA polymerase with TD60 PCR thermal cycling conditions ([@b45-0060755]). The *Ka* mice and embryos were genotyped using the primers Ark1085_F 5′-CCTTCTTCCGTTACATGCG-3′ and Ark1086_R 5′-CTGAGC-CTCCTCGATCC-3′ and sexed using primers Ark1002_F 5′-GAGGTCATGAAGGTCAG-3′ and Ark1003_R 5′-GGGCATAA-ACTTTCCAG-3′.

Mutation detection
------------------

Mutation detection was performed by direct sequencing of PCR amplicons from genomic DNA isolated from affected animals and the appropriate parental strains (C3H/HeH and BALB/c OlaHsd) ([@b10-0060755]). All primers correspond to intron sequence such that coding sequence and intron/exon boundaries were examined for mutations. The oligonucleotides used for sequencing *Zic3* were: fragment 1, Ark207_F 5′-TAGGAAAGTTGCAGCTCC-3′ and Ark208_R 5′-ATAGTTAGGGAACTGCGC-3′; fragment 2, Ark209_F 5′-CTACTTGCTCTTTCCTGG-3′ and Ark210_R 5′-TGGTACTGAAAGGTCTCG-3′; fragment 3, Ark211_F 5′-CAGATGCTATGTCCTTCC-3′ and Ark212_R 5′-TTCAAGGT-GTCAGTGCTG-3′; fragment 4, Ark213_F 5′-CTAGGGGTA-TCTATCTCG-3′ and Ark214_R 5′-CTGAGAAAAGGGCAT-AGC-3′.

Whole mount *in situ* hybridization and cDNA clones
---------------------------------------------------

All embryos were dissected from the maternal membranes in PBS with 10% newborn calf serum and staged using morphological criteria ([@b14-0060755]). Embryos were fixed overnight at 4°C in 4% paraformaldehyde in PBS. WMISH was carried out according to standard procedures ([@b50-0060755]; [@b41-0060755]). Probes for WMISH were as previously described: *Zic3* ([@b16-0060755]), *Lhx1* ([@b44-0060755]), *Cer1* ([@b9-0060755]), *Foxa2* ([@b43-0060755]) and *Fgf8* ([@b32-0060755]). After completion of the WMISH, embryos were de-stained in PBT (PBS with 0.1% Tween-20) for 48 hours and post-fixed in 4% paraformaldehyde in PBS for 1 hour at room temperature. Embryos were processed for photography through a glycerol series (50%, 80% and 100%) and photographed on a glass slide.

RT-PCR
------

Embryos, dissected and staged, for RT-PCR were individually frozen in 96-well plates on dry ice and stored at −70°C. Upon geno- and sex-typing of the corresponding embryo tissue, the embryos were pooled in three genotype classes (*Zic3^+/+^*, *Zic3^Ka/X^* and *Zic3^Ka/Y^*). Each pool consisted of ten embryos at 7.5 dpc, four embryos at 8.5 dpc and two embryos at 9.5 dpc. Genomic DNA-free RNA was extracted from each sample using the Ambion RNAqueous 4 PCR kit (Life Technologies). RNA concentration was quantified by Nanodrop spectrophotometry and 500 ng of RNA template included in a random primed cDNA first strand synthesis reaction (Superscript VILO cDNA synthesis kit; Life Technologies). A RT negative control synthesis reaction was performed in parallel from each RNA sample. To confirm absence of contaminating genomic DNA in the original RNA samples, amplification from each cDNA sample was performed using primers Ark364 and Ark311 (located in exons 2 and 3, respectively, of *Zic3*) using Abgene DNA polymerase (with buffer: 10 mM Tris-HCl, pH 8.3, at 25°C, 50 mM KCl, 1.5 mM MgCl~2~) and TD60 PCR thermal cycling conditions with an extension time of 45 seconds ([@b45-0060755]). PCR products were analysed by agarose gel electrophoresis. Amplification from genomic DNA produces a 1006-bp product whereas that from cDNA results in a 162-bp product. For allele-specific PCR, each cDNA (0.5 μl) was used in the genotyping assay.

Plasmids
--------

All plasmid construction used standard molecular biology procedures. The Gateway® Recombination Cloning Technology (Life Technologies™) was used to generate V5-epitope-tagged expression plasmids. The appropriate cDNA was transferred to the pENTR™3C vector that had been linearized with *EcoR*I (NEB) and dephosphorylated with Antarctic Phosphatase (NEB) to produce an 'entry' clone. Four entry clones were generated as follows.

pENTR™3C-ZIC3-wt: a full length ZIC3 cDNA was recovered from the HA-ZIC3-wt expression plasmid (a gift from Stephanie Ware, Cincinnati Children's Hospital Medical Center, OH) ([@b46-0060755]) by PCR with oligonucleotides Ark1152_F 5′-ATCCGGTACCGAATTCACCCTCTCTCACTTCGG-3′ and Ark1153_R 5′-GTGCGGCCGCGAATTCCCGCTCTAGAAC-TAGTGG-3′. This amplicon was cloned using In-Fusion™ Dry-Down PCR Cloning System (Clontech) into pENTR™3C vector (Life Technologies).

pENTR™3C-ZIC3-katun: the HA-ZIC3-wt plasmid was subjected to site-directed mutagenesis with the QuikChange® II Site-Directed Mutagenesis Kit (Stratagene) using oligonucleotides Ark1006_F 5′-GCCTATCAAGCAGTAGCTGTCGTGCAAGTG-3′ and Ark1007_R 5′-CACTTGCACGACAGCTACTGCTTG-ATAGGC-3′. The ZIC3-katun cDNA was amplified and cloned as for ZIC3-wt into pENTR™3C.

pENTR^™^3C-ZIC2-wt: a full length ZIC2 cDNA was PCR amplified from pcDNA-ZIC2 (a gift from Maral Mouradian, Robert Wood Johnson Medical School, NJ) ([@b51-0060755]), using oligonucleotides: Ark1150_F 5′-ATCCGGTACCGAATTCAGTG-TGGTGGAATTCCTGGCC-3′ and Ark1168_R 5′-GTGCGGCC-GCGAATTCGAGGGTTAGGGATAGGCTTAC-3′ and cloned into pENTR™3C using the In-Fusion™ Dry-Down PCR Cloning System.

pENTR™3C-ZIC5-wt: a full length ZIC5-wt cDNA was excised from pCMV6-XL5-ZIC5 (Origene) via *Eco*RI digestion and ligated into pENTR™3C using T4 DNA ligase (NEB). Entry clones for all other ZIC3 mutant plasmids were created via site-directed mutagenesis of pENTR™3C-ZIC3-wt with the QuikChange II Site-Directed Mutagenesis Kit (Stratagene). Primers used to introduce mutations were as follows: pENTR™3C-ZIC3-C268X, Ark1399_F 5′-CGGCCCAAGAAGAGCTGAGACCGGACCTTCAGC-3′ and Ark1400_R GCTGAAGGTCCGGTCTCAGCTCTTCTTGGGC-CG-3′; pENTR™3C-ZIC3-Q292X, Ark1401_F 5′-GTGGGGGG-CCCGGAGTAGAACAACCACGTCTGC-3′ and Ark1402_R 5′-GCAGACGTGGTTGTTCTACTCCGGGCCCCCCAC-3′; pENTR™3C-ZIC3-1507insTT, Ark1403_F 5′-CCGAGTGC-ACACGGGCTTGAGAAGCCCTTCCCA-3′ and Ark1404_R 5′-TGGGAAGGGCTTCTCAAGCCCGTGTGCACTCGG-3′; pENTR™3C-ZIC3-K408X, Ark1405_F 5′-CTGCGCAAACAC-ATGTAGGTTCATGAATCTCAA-3′ and Ark1406_R 5′-TTGA-GATTCATGAACCTACATGTGTTTGCGCAG-3′.

In each case, the inserts from the entry clones were transferred to the destination clone pcDNA3.1/nV5-DEST™ (Life Technologies) via a Gateway® LR Clonase reaction (as per manufacturer's instructions; Life Technologies) to produce the following plasmids: V5-ZIC3-wt, V5-ZIC3-katun, V5-ZIC3-C268X, V5-ZIC3-Q292X, V5-ZIC3-1507insTT, V5-ZIC3-K408X, V5-ZIC2-wt and V5-ZIC5-wt. To generate the EGFP-tagged ZIC3 constructs, ZIC3 was amplified from HA-ZIC3-wt or HA-ZIC3-katun using the following primers: Ark1208_F 5′-GAGCTCAAGCTTCGAATTCTACCC-TCTCTCACTTCGG-3′ and Ark1209_R 5′-TACCGTCGAC-TGCAGAATTCCCGCTCTAGAACTAGTG-3′. The PCR product was cloned into pEGFP-C1 (linearized with *Eco*RI and dephosphorylated with Antartic Phosphatase) using the In-Fusion™ Dry-Down PCR Cloning System. The *Apoe* reporter construct pXP2-Apoe (−189/+1) was a gift from Francisco Zafra (Centro de Biología Molecular, Universidad Autonoma de Madrid, Spain) ([@b42-0060755]). The TOPflash and FOPflash vectors contain four optimal TCF binding sites or four mutant TCF binding sites, respectively, upstream of a minimal *c-Fos* promoter and luciferase cDNA. These vectors and the pCAN-β-catenin-ΔN89 expression construct ([@b36-0060755]) were a gift from Sabine Tejpar (Molecular Digestive Oncology, Katholieke Universiteit Leuven, Belgium) ([@b39-0060755]).

Cell culture and transfection
-----------------------------

Mammalian cell lines COS-7, NIH3T3 and HEK293T were cultured in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies), supplemented with 10% (v/v) fetal bovine serum (Life Technologies), 2 mM L-glutamine (Life Technologies) and 0.1 mM non-essential amino acid solution (Life Technologies) at 37°C in humidified air. For transient transfections, cells were transfected with either 0.4--0.6 μg or 3--4 μg of the mammalian expression plasmid DNA using Lipofectamine™ 2000 (Life Technologies) according to the manufacturer's guidelines.

Immunofluorescence staining, microscopy and quantification of subcellular localization
--------------------------------------------------------------------------------------

Cells were prepared for immunofluorescence microscopy as previously described ([@b30-0060755]) and viewed using the LSM 5 Pascal (ZEISS) confocal microscope. At least 100 transfected cells per experiment were scored blind as follows. For each cell, the nuclear and cytoplasmic compartment was traced using the Intuos® 2 graphics tablet (Wacom) and the average fluorescence intensity for each compartment of the cell was measured with ImageJ analysis software (NIH). The values from the 100 scored cells were averaged to give the percentage nuclear and percentage cytoplasmic localization for the experiment. Three independent experiments were conducted and the percentage localization in each cellular compartment averaged across the three experiments. For statistical analysis, GenStat (VSN International) was used to perform a nonorthogonal factorial ANOVA. Images were assembled in Adobe Photoshop CS7.

Subcellular fractionation, SDS-PAGE and western blotting
--------------------------------------------------------

HEK293T cells grown on 35-mm tissue culture dishes or 12-well tissue culture plates (Corning®) were lysed and fractioned into nuclear and cytoplasmic fractions using the NE-PER kit (Pierce) according to the manufacturer's protocol. CERI and NERI lysis buffers were supplemented with protease inhibitors (complete, EDTA-free protease inhibitor cocktail, Roche). Then, 2 mM DTT (Sigma Aldrich) and 1× NuPAGE LDS Sample Buffer (Life Technologies) were added to nuclear and cytoplasmic fractions and the samples heated for 5 minutes at 90°C. Samples were then loaded onto 8%, 10% or 12% SDS-PAGE gels and run at 100 V. Proteins were transferred to PVDF membranes (Millipore) via wet transfer at 15 V for 16 hours. Membranes were blocked overnight at 4°C with a solution of 5% skim milk powder, PBS and 0.2% Tween 20 (Sigma Aldrich) (western blot blocking buffer) before being immunoblotted using standard western blotting techniques. To detect protein bands, blots were incubated with SuperSignal West Pico reagent (as per manufacturer's guidelines; Pierce) then exposed to film (Amersham Hyperfilm MP, GE Life Sciences). Developed films were scanned and assembled in Adobe Illustrator CS5.1.

Antibodies
----------

Primary antibodies used were: goat polyclonal anti-Zic3 N-19 (1:500 dilution for western blot; Santa Cruz Biotechnology, sc-28154), mouse monoclonal anti-HA (1:100 dilution for immunofluorescence, 1:4000 dilution for western blot; Sigma, H3663), mouse monoclonal anti-V5 (1:200 dilution for immunofluorescence, 1:3000 dilution for western blot; Life Technologies, R960-25), rabbit polyclonal anti-GFP (1:300 dilution for immunofluorescence, 1:1000 dilution for western blot; Cell Signaling, 2555), rabbit polyclonal anti-Lamin B1 (1:1000 dilution for immunofluorescence; Abcam, ab16048), mouse monoclonal anti-β-tubulin (1:1000 dilution for western blot; Abcam, ab7792), mouse monoclonal anti-TATA binding protein (TBP) (1:2000 dilution for western blot; Abcam, ab818) and goat polyclonal β-catenin C-18 (1:500 dilution for western blot; Santa Cruz Biotechnology, sc-1496). Secondary antibodies used for immunofluorescence (all at 1:500 dilution) were Alexa-Fluor-594-and Alexa-Fluor-488-conjugated donkey anti-mouse, anti-goat and anti-rabbit (Molecular Probes, Life Technologies). Secondary antibodies used for western blot (all at 1:5000 dilution) were horseradish peroxidase-conjugated rabbit anti-mouse, rabbit anti-goat and goat anti-rabbit (Zymed, Life Technologies). All antibodies were diluted in blocking buffer.

Luciferase reporter assays
--------------------------

HEK293T cells grown in 12-well tissue culture plates were transfected with the relevant combination of constructs. For ZIC trans-activation assays, a total of 1.2 μg of DNA was added per well: 0.6 μg of the *Apoe* reporter construct and either 0.6 μg of the expression construct or the negative control construct, pcDNA3.1/nV5-DEST™. For ZIC competition assays, a total of 1.2 μg of DNA was added per well: 0.4 μg of the *Apoe* reporter construct, 0.4 μg of the wild-type ZIC expression construct and 0.4 μg of either the competing katun expression construct or the pcDNA3.1/nV5-DEST™ vector when required to equalize the amount of transfected DNA. For the Wnt inhibition assays, a total of 1.5 μg of DNA was transfected per well: 0.5 μg of the TOPflash or FOPflash reporter vectors, 0.5 μg β-catenin-ΔN89 construct and 0.5 μg of the appropriate ZIC3 construct or pcDNA3.1/nV5-DEST™. To assess background Wnt activation levels, one well was transfected with 0.5 μg of the TOPflash or FOPflash reporter vectors and 1 μg of the pcDNA3.1/nV5-DEST™ vector. Either 8 hours (for the ZIC trans-activation and competition assays) or 5.5 hours (for the Wnt inhibition assays) post-transfection, cells were dissociated from the growth surface using 0.05 g/l trypsin (Life Technologies) and plated in triplicate onto a solid white tissue-culture treated 96-well plate (Costar®, CLS3917). To avoid any position bias error of the luminometer, sample order was randomized for each independent experimental repeat. The remaining cells were re-plated for SDS-PAGE and western blot analysis and lysed at the time of the reporter assay. Either 16 (for ZIC trans-activation and competition assays) or 19.5 hours (for Wnt inhibition assays) after re-plating, cells in each well were lysed by incubation with 100 μl of a 1:1 dilution of luciferase substrate (ONE-Glo™ Luciferase Assay System, Promega) with DMEM and the luminescence from each well measured in a GloMax®-96 Microplate Luminometer (Promega). The luciferase activity was normalized to the pcDNA3.1/nV5-DEST™ negative control and the average value and standard deviation calculated from the three internal repeats. At least three independent experiments were performed for each assay, with one representative experiment shown. For statistical analysis, GenStat was used to perform ANOVA with Fischer's unprotected post ad hoc test.
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